A 16% gap between what Medicare pays for a lab test and what a private insurer pays for the identical test is the number driving a new preliminary fee schedule from the Centers for Medicare & Medicaid Services. CMS says closing most of that gap would save taxpayers roughly $1 billion a year once the new rates take hold, and it has built in a slow phase-in so no single test’s payment falls off a cliff in one year. The preliminary numbers, released this week, are not final: a public comment period is open now, and the rates that actually take effect will be published in November. For the millions of Medicare beneficiaries who get routine bloodwork, genetic panels or other lab tests ordered as part of ordinary care, the schedule sets what the government pays the lab on their behalf, a number separate from any deductible or coinsurance the beneficiary sees on a statement.
Medicare’s 16% Gap With Private Payers
CMS says its own analysis found Medicare has been paying about 16% more for laboratory services than private payors pay for the same tests, a gap the agency attributes to a payment formula for the Clinical Laboratory Fee Schedule that has not kept pace with the rates insurers actually negotiate in the private market. Closing that spread is the stated purpose of the new preliminary rates, which CMS estimates would save an estimated $1 billion annually once fully in effect. “Taxpayers and Medicare patients have been paying excessive rates to labs for years,” CMS Administrator Dr. Mehmet Oz said in the agency’s announcement, “but with some help from Congress, CMS is working to ensure that Medicare isn’t paying more than private insurers for the exact same tests.” The release does not describe any change to what a Medicare beneficiary personally owes for a covered lab test; the adjustment is to what CMS pays the lab, not to a patient’s copay or deductible structure. Oz’s reference to “some help from Congress” points to the statutory basis CMS is using to realign the Clinical Laboratory Fee Schedule with private-market rates rather than the older, separately calculated formula the schedule has historically used, which is also why the agency built the multi-year phase-in into the preliminary numbers instead of moving straight to the full gap in one cycle.
Inside the kit: a medication and cost tracker for keeping a running record of what Medicare pays and bills for recurring lab work and prescriptions, and 51 state Medicare cost-help packs that lay out the assistance programs available where a beneficiary actually lives. Open the cost tracker and the state packs in The Medicare Cost & Coverage Protection Kit.
Which Tests Move, and By How Much
CMS’s companion fact sheet breaks the preliminary rates down code by code. Of 1,947 applicable test codes, 1,171 would see a lower weighted median payment, 186 would see a higher one, and 169 would stay equal under the preliminary schedule. The average potential change across the board runs about 16% lower, matching the overall gap CMS cited against private payers, but the movement is uneven by category. Genomic sequencing procedures face roughly a 23% cut, molecular pathology about 22%, and general chemistry tests about 16%, according to the same fact sheet — meaning a lab that runs a heavy mix of genomic or molecular tests would see a steeper preliminary reduction than one focused on routine chemistry panels. The 186 codes moving higher under the preliminary schedule show the realignment is not a blanket cut in every direction; a smaller number of tests where Medicare had been paying below the private-market rate would see their payment rise, even as the overall average moves down. The 169 codes CMS lists as unchanged are, by definition, tests where the agency’s existing rate already sits close to what private payers pay for the same procedure.
The 15% Annual Cap Through 2029
CMS is not applying the full 16% gap in a single year. By law, the agency says, no individual test’s payment rate can be reduced by more than 15% in a given year through 2029, a statutory guardrail meant to keep any single lab from absorbing an abrupt payment cut. That cap means a test facing the steepest preliminary reductions, like the roughly 23% figure projected for genomic sequencing, would be phased down over more than one payment cycle rather than dropping all at once on January 1, 2027. For beneficiaries, the practical effect of the cap is continuity: labs performing commonly ordered tests are less likely to stop offering them or referring patients elsewhere over a single year’s reimbursement shock.
The Path to November’s Final Rates
The numbers released this week remain preliminary. CMS has opened a 30-day public comment period starting from the announcement, during which labs, medical societies and other stakeholders can respond to the proposed code-level changes before they are locked in. The agency says it will publish final CY 2027 lab fee schedule rates on its website in November 2026, ahead of the rates taking effect on January 1, 2027. Whether the final numbers match this week’s preliminary figures, including the 16% average reduction and the $1 billion savings estimate, depends in part on what the comment period surfaces; CMS’s own fact sheet frames November’s release as the point at which the preliminary schedule becomes the operative one for laboratories billing Medicare, giving beneficiaries and the labs that bill on their behalf a window between the November publication and the January 1 effective date to see the exact code-level rates before they take hold.
Tracking a Lab Bill While the Fee Schedule Is Still Preliminary
CMS’s preliminary lab fee schedule names the tests moving and by roughly how much, but a beneficiary reading their own lab bill or Medicare Summary Notice still has to match a specific charge against that changing rate table, and the preliminary numbers due out in November could shift before they’re final. That comparison work does not have a single official worksheet designed for a household to run it themselves.
The Medicare Cost & Coverage Protection Kit includes a medication and cost tracker for logging recurring charges like lab work alongside prescriptions, plus the prior-authorization appeal steps for questioning a bill or a denial that looks out of line with what the plan should be paying.
Open the cost tracker in The Medicare Cost & Coverage Protection Kit.
This article was produced with AI assistance and checked against the primary sources linked above.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
